Form 4: Collins Helen Louise reports acquisition/exercise transactions in ELVN

Rhea-AI Filing Summary

Collins Helen Louise reported acquisition or exercise transactions in a Form 4 filing for ELVN. The filing lists transactions totaling 175,000 shares. Following the reported transactions, holdings were 150,000 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Collins Helen Louise

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	150,000	$0.00	--
Grant/Award	Common Stock	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 150,000 shares (Direct); Common Stock — 25,000 shares (Direct)

Footnotes (1)

1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Helen Louise

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		A		25,000(1)	A	$0	25,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$27.16	02/12/2026		A		150,000		(2)	02/12/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.

2. 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

	/s/ Ben Hohl, by power of attorney	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Enliven Therapeutics (ELVN) CMO Helen Collins receive?

Helen Collins received stock options for 150,000 shares and 25,000 restricted stock units. The RSUs each represent one share of common stock, and both awards vest over several years, contingent on her continuing as a service provider to Enliven Therapeutics.

How do the new RSUs for Enliven Therapeutics (ELVN) CMO vest?

The 25,000 RSUs granted to Helen Collins vest over time. One-quarter vests on March 1, 2027, and the remaining three-quarters vest in equal 1/16 increments each June 1, September 1, December 1, and March 1 afterward, subject to continued service.

What is the vesting schedule for Helen Collins’ 150,000 stock options at Enliven (ELVN)?

The 150,000 stock options vest over four years. One-quarter of the option shares vest on February 12, 2027, and the remaining three-quarters vest in equal 1/48 monthly installments thereafter, provided Helen Collins remains a service provider to Enliven Therapeutics.

Are Helen Collins’ Enliven (ELVN) equity awards open-market purchases?

No, these transactions are grants, not open-market purchases. The Form 4 shows stock option and RSU awards coded as acquisitions under a grant or award, meaning they were issued as compensation rather than bought on the open market for cash.

How many Enliven (ELVN) RSUs does Helen Collins hold after this Form 4?

After this report, Helen Collins holds 25,000 restricted stock units representing Enliven common shares. These RSUs will convert into shares only as they vest over time, and vesting is conditioned on her continued role as a service provider to the company.

What does each Enliven Therapeutics (ELVN) RSU granted to Helen Collins represent?

Each RSU granted to Helen Collins represents a contingent right to receive one share of Enliven’s common stock. The shares are not issued immediately; they are delivered only as the RSUs vest according to the specified schedule and continued service conditions.